Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Pro-cognitive effects of dual tacrine derivatives acting as cholinesterase inhibitors and NMDA receptor antagonists

M. Chvojkova, D. Kolar, K. Kovacova, L. Cejkova, A. Misiachna, K. Hakenova, L. Gorecki, M. Horak, J. Korabecny, O. Soukup, K. Vales

. 2024 ; 176 (-) : 116821. [pub] 20240531

Language English Country France

Document type Journal Article

Therapeutic options for Alzheimer's disease are limited. Dual compounds targeting two pathways concurrently may enable enhanced effect. The study focuses on tacrine derivatives inhibiting acetylcholinesterase (AChE) and simultaneously N-methyl-D-aspartate (NMDA) receptors. Compounds with balanced inhibitory potencies for the target proteins (K1578 and K1599) or increased potency for AChE (K1592 and K1594) were studied to identify the most promising pro-cognitive compound. Their effects were studied in cholinergic (scopolamine-induced) and glutamatergic (MK-801-induced) rat models of cognitive deficits in the Morris water maze. Moreover, the impacts on locomotion in the open field and AChE activity in relevant brain structures were investigated. The effect of the most promising compound on NMDA receptors was explored by in vitro electrophysiology. The cholinergic antagonist scopolamine induced a deficit in memory acquisition, however, it was unaffected by the compounds, and a deficit in reversal learning that was alleviated by K1578 and K1599. K1578 and K1599 significantly inhibited AChE in the striatum, potentially explaining the behavioral observations. The glutamatergic antagonist dizocilpine (MK-801) induced a deficit in memory acquisition, which was alleviated by K1599. K1599 also mitigated the MK-801-induced hyperlocomotion in the open field. In vitro patch-clamp corroborated the K1599-associated NMDA receptor inhibitory effect. K1599 emerged as the most promising compound, demonstrating pro-cognitive efficacy in both models, consistent with intended dual effect. We conclude that tacrine has the potential for development of derivatives with dual in vivo effects. Our findings contributed to the elucidation of the structural and functional properties of tacrine derivatives associated with optimal in vivo pro-cognitive efficacy.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24013345
003      
CZ-PrNML
005      
20240905133813.0
007      
ta
008      
240725e20240531fr f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.biopha.2024.116821 $2 doi
035    __
$a (PubMed)38823278
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a fr
100    1_
$a Chvojkova, Marketa $u National Institute of Mental Health, Topolova 748, Klecany 250 67, Czech Republic. Electronic address: marketa.chvojkova@nudz.cz
245    10
$a Pro-cognitive effects of dual tacrine derivatives acting as cholinesterase inhibitors and NMDA receptor antagonists / $c M. Chvojkova, D. Kolar, K. Kovacova, L. Cejkova, A. Misiachna, K. Hakenova, L. Gorecki, M. Horak, J. Korabecny, O. Soukup, K. Vales
520    9_
$a Therapeutic options for Alzheimer's disease are limited. Dual compounds targeting two pathways concurrently may enable enhanced effect. The study focuses on tacrine derivatives inhibiting acetylcholinesterase (AChE) and simultaneously N-methyl-D-aspartate (NMDA) receptors. Compounds with balanced inhibitory potencies for the target proteins (K1578 and K1599) or increased potency for AChE (K1592 and K1594) were studied to identify the most promising pro-cognitive compound. Their effects were studied in cholinergic (scopolamine-induced) and glutamatergic (MK-801-induced) rat models of cognitive deficits in the Morris water maze. Moreover, the impacts on locomotion in the open field and AChE activity in relevant brain structures were investigated. The effect of the most promising compound on NMDA receptors was explored by in vitro electrophysiology. The cholinergic antagonist scopolamine induced a deficit in memory acquisition, however, it was unaffected by the compounds, and a deficit in reversal learning that was alleviated by K1578 and K1599. K1578 and K1599 significantly inhibited AChE in the striatum, potentially explaining the behavioral observations. The glutamatergic antagonist dizocilpine (MK-801) induced a deficit in memory acquisition, which was alleviated by K1599. K1599 also mitigated the MK-801-induced hyperlocomotion in the open field. In vitro patch-clamp corroborated the K1599-associated NMDA receptor inhibitory effect. K1599 emerged as the most promising compound, demonstrating pro-cognitive efficacy in both models, consistent with intended dual effect. We conclude that tacrine has the potential for development of derivatives with dual in vivo effects. Our findings contributed to the elucidation of the structural and functional properties of tacrine derivatives associated with optimal in vivo pro-cognitive efficacy.
650    _2
$a zvířata $7 D000818
650    12
$a takrin $x farmakologie $7 D013619
650    12
$a cholinesterasové inhibitory $x farmakologie $7 D002800
650    12
$a receptory N-methyl-D-aspartátu $x antagonisté a inhibitory $x metabolismus $7 D016194
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a krysa rodu Rattus $7 D051381
650    12
$a dizocilpinmaleát $x farmakologie $7 D016291
650    12
$a bludiště - učení $x účinky léků $7 D018782
650    12
$a kognice $x účinky léků $7 D003071
650    12
$a potkani Wistar $7 D017208
650    _2
$a acetylcholinesterasa $x metabolismus $7 D000110
650    _2
$a skopolamin $7 D012601
650    _2
$a antagonisté excitačních aminokyselin $x farmakologie $7 D018691
650    _2
$a paměť $x účinky léků $7 D008568
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kolar, David $u National Institute of Mental Health, Topolova 748, Klecany 250 67, Czech Republic
700    1_
$a Kovacova, Katarina $u National Institute of Mental Health, Topolova 748, Klecany 250 67, Czech Republic; Department of Animal Physiology and Ethology, Faculty of Natural Sciences, Comenius University, Ilkovicova 6, Bratislava 4 842 15, Slovak Republic
700    1_
$a Cejkova, Lada $u National Institute of Mental Health, Topolova 748, Klecany 250 67, Czech Republic
700    1_
$a Misiachna, Anna $u Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, Prague 142 20, Czech Republic; Department of Physiology, Faculty of Science, Charles University in Prague, Albertov 6, Prague 2 12843, Czech Republic
700    1_
$a Hakenova, Kristina $u National Institute of Mental Health, Topolova 748, Klecany 250 67, Czech Republic; Third Faculty of Medicine, Charles University, Ruska 87, Prague 10 100 00, Czech Republic
700    1_
$a Gorecki, Lukas $u Biomedical Research Center, University Hospital Hradec Kralove, Sokolska 581, Hradec Kralove 500 05, Czech Republic; Department of Toxicology and Military Pharmacy, Military Faculty of Medicine, University of Defence, Trebesska 1575, Hradec Kralove 500 02, Czech Republic
700    1_
$a Horak, Martin $u Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, Prague 142 20, Czech Republic
700    1_
$a Korabecny, Jan $u Biomedical Research Center, University Hospital Hradec Kralove, Sokolska 581, Hradec Kralove 500 05, Czech Republic; Department of Toxicology and Military Pharmacy, Military Faculty of Medicine, University of Defence, Trebesska 1575, Hradec Kralove 500 02, Czech Republic
700    1_
$a Soukup, Ondrej $u Biomedical Research Center, University Hospital Hradec Kralove, Sokolska 581, Hradec Kralove 500 05, Czech Republic; Department of Toxicology and Military Pharmacy, Military Faculty of Medicine, University of Defence, Trebesska 1575, Hradec Kralove 500 02, Czech Republic
700    1_
$a Vales, Karel $u National Institute of Mental Health, Topolova 748, Klecany 250 67, Czech Republic; Third Faculty of Medicine, Charles University, Ruska 87, Prague 10 100 00, Czech Republic
773    0_
$w MED00005486 $t Biomedicine & pharmacotherapy $x 1950-6007 $g Roč. 176 (20240531), s. 116821
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38823278 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20240905133807 $b ABA008
999    __
$a ok $b bmc $g 2143265 $s 1225211
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 176 $c - $d 116821 $e 20240531 $i 1950-6007 $m Biomedicine & pharmacotherapy $n Biomed Pharmacother $x MED00005486
LZP    __
$a Pubmed-20240725

Find record

Citation metrics

Logged in users only

Archiving options

Loading data ...